Sensei Biotherapeutics Inc has a consensus price target of $5.6 based on the ratings of 5 analysts. The high is $10 issued by Piper Sandler on March 10, 2022. The low is $4 issued by Citigroup on June 3, 2024. The 3 most-recent analyst ratings were released by Citigroup, HC Wainwright & Co., and Stephens & Co. on June 3, 2024, May 24, 2024, and May 24, 2024, respectively. With an average price target of $4.33 between Citigroup, HC Wainwright & Co., and Stephens & Co., there's an implied 547.35% upside for Sensei Biotherapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/03/2024 | Buy Now | 497.55% | Citigroup | Samantha Semenkow | → $4 | Reinstates | Buy → Buy | Get Alert |
05/24/2024 | Buy Now | 497.55% | HC Wainwright & Co. | Edward White | → $4 | Reiterates | Buy → Buy | Get Alert |
05/24/2024 | Buy Now | 646.94% | Stephens & Co. | Sudan Loganathan | $5 → $5 | Reiterates | Overweight → Overweight | Get Alert |
05/14/2024 | Buy Now | 646.94% | Stephens & Co. | Sudan Loganathan | → $5 | Initiates | → Overweight | Get Alert |
12/04/2023 | Buy Now | 497.55% | HC Wainwright & Co. | Edward White | → $4 | Initiates | → Buy | Get Alert |
12/13/2022 | Buy Now | 796.33% | Citigroup | Samantha Semenkow | → $6 | Initiates | → Buy | Get Alert |
10/03/2022 | Buy Now | 646.94% | Oppenheimer | Francois Brisebois | → $5 | Upgrade | Perform → Outperform | Get Alert |
03/10/2022 | Buy Now | 1393.88% | Piper Sandler | Joseph Catanzaro | $12 → $10 | Maintains | Overweight | Get Alert |
The latest price target for Sensei Biotherapeutics (NASDAQ:SNSE) was reported by Citigroup on June 3, 2024. The analyst firm set a price target for $4.00 expecting SNSE to rise to within 12 months (a possible 497.55% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Sensei Biotherapeutics (NASDAQ:SNSE) was provided by Citigroup, and Sensei Biotherapeutics their buy rating.
The last upgrade for Sensei Biotherapeutics Inc happened on October 3, 2022 when Oppenheimer raised their price target to $5. Oppenheimer previously had a perform for Sensei Biotherapeutics Inc.
There is no last downgrade for Sensei Biotherapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sensei Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sensei Biotherapeutics was filed on June 3, 2024 so you should expect the next rating to be made available sometime around June 3, 2025.
While ratings are subjective and will change, the latest Sensei Biotherapeutics (SNSE) rating was a with a price target of $0.00 to $4.00. The current price Sensei Biotherapeutics (SNSE) is trading at is $0.67, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.